CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) Trial.
Michael L JamesJesse TroyNathaniel NowackiJordan KomisarowChrista B SwisherKristi TuckerKevin HattonMarc A BabiBradford B WorrallCharles AndrewsDaniel WooPeter G KranzChristopher LascolaMaureen MaughanDaniel T Laskowitznull nullPublished in: Neurocritical care (2021)
CN-105 administration represents an excellent translational candidate for treatment of acute ICH because of its safety, dosing feasibility, favorable pharmacokinetics, and possible improvement in neurological recovery.